victoza glp 1 First Generic of Once-Daily GLP-1 Injection Approved for Diabetes Victoza (Liraglutide) GLP-1 injection -
Description
Experts warn that misuse of Ozempic and Mounjaro could trigger serious health risks without medical supervision.
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
Here are some of the side effects you should know about.
The 'Insurance Skip' play
The more meaningful question is not: Do patients regain weight after stopping GLP-1s? It is: How should we transition patients from pharmacologic support to long-term weight maintenance? Obesity is a chronic disease
Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.
